You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNadroparin
Accession NumberDB08813
TypeSmall Molecule
GroupsApproved
DescriptionNadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
FraxiparineSolution9500 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1998-02-05Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Fraxiparine ForteSolution19000 unitIntravenous; SubcutaneousAspen Pharma Trading Limited1999-06-22Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nadroparin calcium
37270-89-6
ThumbNot applicableDBSALT001135
Categories
UNIINot Available
CAS number9041-08-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationNadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction
Structured Indications
PharmacodynamicsNadroparin is a low molecular weight heparin that is composed of a heterogeneous mixture of sulfated polysaccaride glycosaminoglycan chains. Th mean molecular weight is approximately 4300 daltons. The ratio of anti-Xa activity to anti-IIa is 3.5:1 whereas it is about 1:1 for heparin. Its use should be avoided in patients with a creatinine clearance less than 40mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Mechanism of actionThe mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.
TargetKindPharmacological actionActionsOrganismUniProt ID
Antithrombin-IIIProteinyes
potentiator
HumanP01008 details
P-selectinProteinunknown
inhibitor
HumanP16109 details
Proto-oncogene c-FosProteinunknown
inhibitor
HumanP01100 details
Myc proto-oncogene proteinProteinunknown
inhibitor
HumanP01106 details
Related Articles
AbsorptionAbsorption is linear. The bioavailability of nadroparin after subcutaneous administration is about 89%.
Volume of distribution

3.59L

Protein bindingMuch lower compared to heparin, which has over 90% protein bound.
Metabolism

Nadroparin is metabolized in the liver.

Route of eliminationNadroparin is eliminated via the kidneys through non-saturable mechanisms.
Half lifeIn healthy patients, the half life is between 3.5hrs to 11.2hrs following subcutaneous administration.
Clearance

The clearance of nadroparin is 21.4 +/- 7.0mL/min

ToxicityOsteopenia with extended use, skin necrosis, thrombocytosis, severe immunologically-mediated thrombocytopenia, eosinophilia (rare), calcinosis rarely occurs at the injection site, severe bleeding, transient elevation of liver transaminases.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Nadroparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Nadroparin.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Nadroparin.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Nadroparin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Nadroparin.Approved
AliskirenNadroparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Nadroparin.Approved
AltrenogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Nadroparin.Investigational
AmilorideNadroparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Nadroparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Nadroparin.Approved
AncrodAncrod may increase the anticoagulant activities of Nadroparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Nadroparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Nadroparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Nadroparin.Approved
Antithrombin III humanNadroparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Nadroparin.Approved
ApremilastApremilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AprotininThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Nadroparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Nadroparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Nadroparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Nadroparin.Approved
Azilsartan medoxomilNadroparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nadroparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Nadroparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Nadroparin.Approved
BenazeprilNadroparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Nadroparin.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Nadroparin.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Nadroparin.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Nadroparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Nadroparin.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Nadroparin.Investigational
CanagliflozinNadroparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanNadroparin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilNadroparin may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Nadroparin.Approved
CaptoprilNadroparin may increase the hyperkalemic activities of Captopril.Approved
CarprofenCarprofen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Nadroparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
CertoparinNadroparin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Nadroparin.Withdrawn
CilazaprilNadroparin may increase the hyperkalemic activities of Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Nadroparin.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Nadroparin.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Nadroparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Nadroparin is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Nadroparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Nadroparin.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Nadroparin.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Nadroparin.Approved
DalteparinDalteparin may increase the anticoagulant activities of Nadroparin.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Nadroparin.Investigational
DesirudinNadroparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Nadroparin.Investigational
DesogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Desogestrel.Approved
DextranNadroparin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nadroparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nadroparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nadroparin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Nadroparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Nadroparin.Approved
DienogestThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Nadroparin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Nadroparin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Nadroparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Nadroparin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Nadroparin.Investigational
DydrogesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Nadroparin.Investigational
EbselenEbselen may increase the anticoagulant activities of Nadroparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Nadroparin.Approved
EnalaprilNadroparin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatNadroparin may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Nadroparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Nadroparin.Approved
EplerenoneNadroparin may increase the hyperkalemic activities of Eplerenone.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Nadroparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Nadroparin.Approved
EprosartanNadroparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Nadroparin.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Nadroparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Nadroparin.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Nadroparin.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Nadroparin.Approved
EtonogestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Nadroparin.Approved
exisulindexisulind may increase the anticoagulant activities of Nadroparin.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Nadroparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Nadroparin.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Nadroparin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
FluindioneNadroparin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Nadroparin.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
FondaparinuxNadroparin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ForasartanNadroparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilNadroparin may increase the hyperkalemic activities of Fosinopril.Approved
GabexateNadroparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Nadroparin.Investigational
GestodeneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Nadroparin.Approved
HeparinHeparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Nadroparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Nadroparin.Investigational
HirulogHirulog may increase the anticoagulant activities of Nadroparin.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Nadroparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nadroparin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nadroparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Nadroparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Nadroparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Nadroparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical
idraparinuxNadroparin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Nadroparin.Approved, Investigational
ImidaprilNadroparin may increase the hyperkalemic activities of Imidapril.Investigational
IndobufenIndobufen may increase the anticoagulant activities of Nadroparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Nadroparin.Withdrawn
IrbesartanNadroparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Nadroparin.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Nadroparin.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Nadroparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Nadroparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Nadroparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Nadroparin.Approved
LevonorgestrelThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nadroparin.Approved
LisinoprilNadroparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Nadroparin.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Nadroparin.Approved
LosartanNadroparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Nadroparin.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Nadroparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Nadroparin.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Nadroparin.Approved
Megestrol acetateThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Nadroparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Nadroparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Nadroparin.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Nadroparin.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Nadroparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Nadroparin.Investigational
MoexiprilNadroparin may increase the hyperkalemic activities of Moexipril.Approved
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Nadroparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Nadroparin.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Nadroparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Nadroparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Nadroparin.Investigational
NepafenacNepafenac may increase the anticoagulant activities of Nadroparin.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Nadroparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Nadroparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Nadroparin.Investigational
NomegestrolThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.Approved
OlmesartanNadroparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Nadroparin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nadroparin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nadroparin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatNadroparin may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Nadroparin.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Nadroparin.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Nadroparin.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Nadroparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Nadroparin.Withdrawn
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Nadroparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Nadroparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Nadroparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Nadroparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PerindoprilNadroparin may increase the hyperkalemic activities of Perindopril.Approved
PhenindionePhenindione may increase the anticoagulant activities of Nadroparin.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Nadroparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Nadroparin.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Nadroparin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Nadroparin.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Nadroparin.Approved
ProgesteroneThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Nadroparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Nadroparin.Approved
Protein CNadroparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanNadroparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNadroparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Nadroparin.Investigational
QuinaprilNadroparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Nadroparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Nadroparin.Investigational
RamiprilNadroparin may increase the hyperkalemic activities of Ramipril.Approved
RescinnamineNadroparin may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Nadroparin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Nadroparin.Approved
ReviparinNadroparin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Nadroparin.Approved
RivaroxabanNadroparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Nadroparin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Nadroparin.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Nadroparin.Investigational
SacubitrilNadroparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Nadroparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Nadroparin.Approved
SaprisartanNadroparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinNadroparin may increase the hyperkalemic activities of Saralasin.Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Nadroparin.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Nadroparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Nadroparin.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Nadroparin.Approved, Vet Approved
SpiraprilNadroparin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneNadroparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Nadroparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Nadroparin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Nadroparin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nadroparin.Approved
SulindacSulindac may increase the anticoagulant activities of Nadroparin.Approved
SulodexideSulodexide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Nadroparin.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Nadroparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nadroparin.Approved
TasosartanNadroparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanNadroparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilNadroparin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Nadroparin.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Nadroparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Nadroparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Nadroparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Nadroparin.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Nadroparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Nadroparin.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Nadroparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Nadroparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Nadroparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Nadroparin.Approved
TipranavirTipranavir may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Nadroparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Nadroparin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Nadroparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.Approved
TrandolaprilNadroparin may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Nadroparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Nadroparin.Approved, Investigational
TriamtereneNadroparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Nadroparin.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Nadroparin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Nadroparin.Investigational, Withdrawn
ValsartanNadroparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Nadroparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nadroparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Nadroparin.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
Ym150Nadroparin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Nadroparin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Nadroparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Nadroparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Nadroparin.Withdrawn
Food Interactions
  • Danshen, dong quai, evening primrose oil, gingko, policosanol, willowbark
References
Synthesis ReferenceNot Available
General References
  1. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 Apr;73(4):630-40. [PubMed:7495071 ]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
  3. Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, Yu AW: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis. 1996 Nov;28(5):721-6. [PubMed:9158210 ]
  4. Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sie P: Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost. 1998 Feb;79(2):338-41. [PubMed:9493587 ]
  5. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H: Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999 May;8(2):119-25. [PubMed:10210734 ]
  6. Ng HJ, Lee LH: Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy. Int J Hematol. 2003 Feb;77(2):185-7. [PubMed:12627856 ]
  7. Breddin HK: Prophylaxis and treatment of deep-vein thrombosis. Semin Thromb Hemost. 2000;26 Suppl 1:47-52. [PubMed:11011806 ]
  8. Haas SK: Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost. 2002 Dec;28(6):577-84. [PubMed:12536351 ]
  9. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990 ]
  10. Iaremchuk AIa, Zotov AS, Cheshuk VE, Anikuc'ko NF, Zakhartseva LM, Diatel MV, Kravchenko AV, Lobanova OE, Sidorchuk OI: [Clinical effectiveness of nadroparin calcium in the surgical treatment of breast cancer]. Vopr Onkol. 2003;49(2):205-8. [PubMed:12785206 ]
  11. Vitale FV, Rotondo S, Sessa E, Antonelli G, Colina P, Parisi A, Giamo V, Ferrau F: Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. J Oncol Pharm Pract. 2011 Jun;17(2):141-4. doi: 10.1177/1078155209353465. Epub 2009 Dec 16. [PubMed:20015933 ]
  12. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009 Oct;10(10):943-9. doi: 10.1016/S1470-2045(09)70232-3. Epub 2009 Aug 31. [PubMed:19726226 ]
External LinksNot Available
ATC CodesB01AB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
SolutionIntravenous; Subcutaneous9500 unit
SolutionIntravenous; Subcutaneous19000 unit
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322. [PubMed:9108990 ]
  2. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sialic acid binding
Specific Function:
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.
Gene Name:
SELP
Uniprot ID:
P16109
Molecular Weight:
90833.105 Da
References
  1. Simonis D, Christ K, Alban S, Bendas G: Affinity and kinetics of different heparins binding to P- and L-selectin. Semin Thromb Hemost. 2007 Jul;33(5):534-9. [PubMed:17629851 ]
  2. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, Gille J: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost. 2006 Mar;95(3):535-40. [PubMed:16525583 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regul...
Gene Name:
FOS
Uniprot ID:
P01100
Molecular Weight:
40694.855 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196 ]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transcriptional activator activity, rna polymerase ii core promoter proximal region sequence-specific binding
Specific Function:
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.
Gene Name:
MYC
Uniprot ID:
P01106
Molecular Weight:
48803.55 Da
References
  1. Nagy Z, Turcsik V, Blasko G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7. [PubMed:19757196 ]
  2. Sustar V, Jansa R, Frank M, Hagerstrand H, Krzan M, Iglic A, Kralj-Iglic V: Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mol Dis. 2009 May-Jun;42(3):223-7. doi: 10.1016/j.bcmd.2009.01.012. Epub 2009 Mar 3. [PubMed:19261492 ]
Comments
comments powered by Disqus
Drug created on June 14, 2011 23:17 / Updated on December 08, 2016 11:46